News Headlines

Display #
FDA clears Optovue’s epi-mapping software
Roche unloads some rights to drug hopeful after asthma trial disappointment
Sleep may not be controlled only by the brain according to research led by Morehouse School of Medicine
New Hampshire sues Purdue Pharma
Startup MyndYou Using AI to Treat Alzheimer’s Disease
Bay Area’s Ardelyx Slashes 28 Percent of Workforce in Restructuring
Mylan cuts forecasts on delays in new drugs
Stimwave Receives FDA 510(k) Clearance for the First Full-Body MRI Scan Ready Wireless Peripheral Nerve Stimulator (PNS) System
Drug Enforcement Administration proposes cutting production of some opioid painkillers
Pharma Entrepreneur Martin Shkreli Found Guilty
Vernalis receives CRL for cough & cold drug
Anti-inflammatory, anti-stress drugs taken before surgery may reduce metastatic recurrence
Herbal medicine shows potential to treat cancer
Drugmakers’ hopes for gene therapy rise despite tiny sales in Europe
MyoKardia Shares Surge on Positive Phase II Results for Heart Muscle Disease
Zynerba shares plunge as cannabis-based epilepsy gel fails study
Gemphire Shares Drop on Disappointing Phase II Results for LDL Drug
Teva Announces FDA Approval of QVAR RediHaler Inhalation Aerosol
Anthem to pare back Obamacare offerings in Nevada and Georgia
FDA Advisory Committee votes in favor of XELJANZ® (tofacitinib citrate) for the treatment of active psoriatic arthritis
Lilly’s acute migraine drug succeeds in Phase III
First-Ever Drug to Treat All Hep C Forms Approved
A new HER2 mutation, a clinical trial and a promising diagnostic tool for metastatic breast cancer
FDA approves treatment for chronic graft versus host disease
US FDA accepts regulatory submission for acalabrutinib and grants Priority Review
Diabetes drug shows potential as disease-modifying therapy for Parkinson's disease
Bristol-Myers Squibb to acquire IFM Therapeutics to strengthen oncology pipeline focus on innate immunity
Teva to Cut 7,000 Jobs, Halt Operations in 45 Countries
Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline
Wal-Mart, Walgreens, CVS turn up the heat on generic drugmaker deals